Inhibitory motor dysfunction in parkinson's disease subtypes

Gong, Tao; Xiang, Yuanyuan; Saleh, Muhammad G.; Gao, Fei; Chen, Weibo; Edden, Richard A.E.; Wang, Guangbin

doi:10.1002/jmri.25865

Cited by 30 publications

(21 citation statements)

References 39 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…We find a consistent significant correlation between MDS-UPDRS scores and GABA levels in the motor cortex, both ON (Panel c) and OFF medication (Panel d), but no significant correlations for the thalamus (Panels a and b) and visual cortex (Panels e and f). GABA, gamma-aminobutyric acid; MDS-UPDRS, Movement Disorders Society Unified Parkinson's Disease Rating Scale; tCre, total creatine from those by Dharmadhikari et al, who showed increased GABA levels in the thalamus of Parkinson's disease patients (Dharmadhikari et al, 2015), or those by Gong et al, who found a reduction of GABA levels in patients in a larger thalamus/basal ganglia voxel (Gong et al, 2017). We considered several possible explanations for this null finding.…”

Section: Parkinson's Disease Is Not Associated With Increased Thalamentioning

confidence: 89%

“…previous studies used a GABA-to-water ratio, whereas here we used a GABA-to-creatine ratio. There is some evidence that in Parkinson's disease, creatine (and NAA) is also reduced in the thalamus and basal ganglia (Gong et al, 2017;Kickler et al, 2007). However, reduced creatine levels in Parkinson's disease would bias us toward confirming, rather than rejecting, our a priori hypothesis of an increased thalamic GABA-to-creatine ratio in Parkinson's disease.…”

Section: Parkinson's Disease Is Not Associated With Increased Thalamentioning

confidence: 89%

“…We considered several possible explanations for this null finding. First, a lack of power due to small sample size is unlikely, since our patient sample (N = 60) was considerably larger than previous samples (n = 22 (Gong et al, 2017), n = 19 (Dharmadhikari et al, 2015). Second, methodological differences may have played a role:…”

Section: Parkinson's Disease Is Not Associated With Increased Thalamentioning

confidence: 93%

“…GABA, gamma-aminobutyric acid; MDS-UPDRS, Movement Disorders Society Unified Parkinson's Disease Rating Scale; tCre, total creatine from those by Dharmadhikari et al, who showed increased GABA levels in the thalamus of Parkinson's disease patients (Dharmadhikari et al, 2015), or those by Gong et al, who found a reduction of GABA levels in patients in a larger thalamus/basal ganglia voxel (Gong et al, 2017). Thus, our findings are different F I G U R E 3 Relationship between GABA and disease severity.…”

Section: Parkinson's Disease Is Not Associated With Increased Thalamentioning

confidence: 97%

“…There is some evidence that in Parkinson's disease, creatine (and NAA) is also reduced in the thalamus and basal ganglia (Gong et al, 2017;Kickler et al, 2007). There is some evidence that in Parkinson's disease, creatine (and NAA) is also reduced in the thalamus and basal ganglia (Gong et al, 2017;Kickler et al, 2007).…”

Section: Parkinson's Disease Is Not Associated With Increased Thalamentioning

confidence: 99%

See 4 more Smart Citations

GABAergic changes in the thalamocortical circuit in Parkinson's disease

Nuland

Ouden

Zach

et al. 2019

Human Brain Mapping

View full text Add to dashboard Cite

Parkinson's disease is characterized by bradykinesia, rigidity, and tremor. These symptoms have been related to an increased gamma-aminobutyric acid (GABA)ergic inhibitory drive from globus pallidus onto the thalamus. However, in vivo empirical evidence for the role of GABA in Parkinson's disease is limited. Some discrepancies in the literature may be explained by the presence or absence of tremor. Specifically, recent functional magnetic resonance imaging (fMRI) findings suggest that Parkinson's tremor is associated with reduced, dopamine-dependent thalamic inhibition. Here, we tested the hypothesis that GABA in the thalamocortical motor circuit is increased in Parkinson's disease, and we explored differences between clinical phenotypes. We included 60 Parkinson patients with dopamine-resistant tremor (n = 17), dopamine-responsive tremor (n = 23), or no tremor (n = 20), and healthy controls (n = 22). Using magnetic resonance spectroscopy, we measured GABA-to-totalcreatine ratio in motor cortex, thalamus, and a control region (visual cortex) on two separate days (ON and OFF dopaminergic medication). GABA levels were unaltered by Parkinson's disease, clinical phenotype, or medication. However, motor cortex GABA levels were inversely correlated with disease severity, particularly rigidity and tremor, both ON and OFF medication. We conclude that cortical GABA plays a beneficial rather than a detrimental role in Parkinson's disease, and that GABA depletion may contribute to increased motor symptom expression.

show abstract

Section: Parkinson's Disease Is Not Associated With Increased Thalamentioning

confidence: 89%

Section: Parkinson's Disease Is Not Associated With Increased Thalamentioning

confidence: 89%

Section: Parkinson's Disease Is Not Associated With Increased Thalamentioning

confidence: 93%

Section: Parkinson's Disease Is Not Associated With Increased Thalamentioning

confidence: 97%

Section: Parkinson's Disease Is Not Associated With Increased Thalamentioning

confidence: 99%

See 3 more Smart Citations

GABAergic changes in the thalamocortical circuit in Parkinson's disease

Nuland

Ouden

Zach

et al. 2019

Human Brain Mapping

View full text Add to dashboard Cite

show abstract

Changes in aspartate metabolism in the medial‐prefrontal cortex of nicotine addicts based on J‐edited magnetic resonance spectroscopy

Yu,

Lin,

et al. 2023

Human Brain Mapping

View full text Add to dashboard Cite

This study aims to explore the changes of the aspartate (Asp) level in the medial‐prefrontal cortex (mPFC) of subjects with nicotine addiction (nicotine addicts [NAs]) using the J‐edited 1H MR spectroscopy (MRS), which may provide a positive imaging evidence for intervention of NA. From March to August 2022, 45 males aged 40–60 years old were recruited from Henan Province, including 21 in NA and 24 in nonsmoker groups. All subjects underwent routine magnetic resonance imaging (MRI) and J‐edited MRS scans on a 3.0 T MRI scanner. The Asp level in mPFC was quantified with reference to the total creatine (Asp/Cr) and water (Aspwater‐corr, with correction of the brain tissue composition) signals, respectively. Two‐tailed independent samples t‐test was used to analyze the differences in levels of Asp and other coquantified metabolites (including total N‐acetylaspartate [tNAA], total cholinine [tCho], total creatine [tCr], and myo‐Inositol [mI]) between the two groups. Finally, the correlations of the Asp level with clinical characteristic assessment scales were performed using the Spearman criteria. Compared with the control group (n = 22), NAs (n = 18) had higher levels of Asp (Asp/Cr: p = .005; Aspwater‐corr: p = .004) in the mPFC, and the level of Asp was positively correlated with the daily smoking amount (Asp/Cr: p < .001; Aspwater‐corr: p = .004). No significant correlation was found between the level of Asp and the years of nicotine use, Fagerstrom Nicotine Dependence (FTND), Russell Reason for Smoking Questionnaire (RRSQ), or Barratt Impulsivity Scale (BIS‐11) score. The elevated Asp level was observed in mPFC of NAs in contrast to nonsmokers, and the Asp level was positively correlated with the amount of daily smoking, which suggests that nicotine addiction may result in elevated Asp metabolism in the human brain.

show abstract

Motion correction in magnetic resonance spectroscopy

Saleh

Edden

Chang

et al. 2020

Magnetic Resonance in Med

Self Cite

View full text Add to dashboard Cite

In vivo proton magnetic resonance spectroscopy and spectroscopic imaging (MRS/MRSI) are valuable tools to study normal and abnormal human brain physiology. However, they are sensitive to motion, due to strong crusher gradients, long acquisition times, reliance on high magnetic field homogeneity, and particular acquisition methods such as spectral editing. The effects of motion include incorrect spatial localization, phase fluctuations, incoherent averaging, line broadening, and ultimately quantitation errors. Several retrospective methods have been proposed to correct motion‐related artifacts. Recent advances in hardware also allow prospective (real‐time) correction of the effects of motion, including adjusting voxel location, center frequency, and magnetic field homogeneity. This article reviews prospective and retrospective methods available in the literature and their implications for clinical MRS/MRSI. In combination, these methods can attenuate or eliminate most motion‐related artifacts and facilitate the acquisition of high‐quality data in the clinical research setting.

show abstract

Inhibitory motor dysfunction in parkinson's disease subtypes

Abstract: 1 Technical Efficacy: Stage 2 J. Magn. Reson. Imaging 2018;47:1610-1615.

Cited by 30 publications

References 39 publications

GABAergic changes in the thalamocortical circuit in Parkinson's disease

GABAergic changes in the thalamocortical circuit in Parkinson's disease

Changes in aspartate metabolism in the medial‐prefrontal cortex of nicotine addicts based on J‐edited magnetic resonance spectroscopy

Motion correction in magnetic resonance spectroscopy

Contact Info

Product

Resources

About